Lisa Schilling
Concepts (377)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electronic Health Records | 13 | 2025 | 1092 | 1.400 |
Why?
| | Periodicals as Topic | 11 | 2008 | 212 | 1.260 |
Why?
| | Decision Support Systems, Clinical | 2 | 2022 | 253 | 1.110 |
Why?
| | Comparative Effectiveness Research | 4 | 2017 | 156 | 0.930 |
Why?
| | Patient-Centered Care | 2 | 2024 | 539 | 0.920 |
Why?
| | Quality Improvement | 6 | 2024 | 1213 | 0.890 |
Why?
| | Data Mining | 2 | 2017 | 115 | 0.850 |
Why?
| | Medical Informatics | 5 | 2024 | 101 | 0.840 |
Why?
| | Needs Assessment | 2 | 2025 | 379 | 0.820 |
Why?
| | Information Storage and Retrieval | 7 | 2021 | 119 | 0.810 |
Why?
| | Decision Support Techniques | 2 | 2025 | 427 | 0.800 |
Why?
| | Publishing | 7 | 2007 | 144 | 0.770 |
Why?
| | Maternal Health Services | 1 | 2024 | 101 | 0.760 |
Why?
| | Ultraviolet Rays | 6 | 2015 | 397 | 0.740 |
Why?
| | Hypertension | 6 | 2025 | 1242 | 0.720 |
Why?
| | Critical Pathways | 1 | 2022 | 98 | 0.700 |
Why?
| | Urinary Tract Infections | 1 | 2023 | 193 | 0.700 |
Why?
| | Dermatology | 8 | 2021 | 120 | 0.660 |
Why?
| | Skin Neoplasms | 7 | 2015 | 837 | 0.590 |
Why?
| | Sunbathing | 2 | 2015 | 16 | 0.590 |
Why?
| | Internet | 10 | 2018 | 669 | 0.590 |
Why?
| | Blood Pressure Determination | 1 | 2018 | 143 | 0.540 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2022 | 444 | 0.490 |
Why?
| | Evidence-Based Medicine | 4 | 2024 | 745 | 0.480 |
Why?
| | Primary Health Care | 8 | 2025 | 1777 | 0.480 |
Why?
| | Medical Record Linkage | 4 | 2024 | 67 | 0.480 |
Why?
| | Safety-net Providers | 2 | 2019 | 118 | 0.470 |
Why?
| | Biomedical Research | 5 | 2021 | 694 | 0.460 |
Why?
| | Patient Outcome Assessment | 1 | 2016 | 131 | 0.440 |
Why?
| | Leadership | 2 | 2024 | 390 | 0.430 |
Why?
| | Foot Deformities, Congenital | 1 | 2013 | 1 | 0.420 |
Why?
| | Attitude of Health Personnel | 4 | 2016 | 1157 | 0.420 |
Why?
| | Health Maintenance Organizations | 2 | 2011 | 107 | 0.420 |
Why?
| | Humans | 77 | 2025 | 138651 | 0.420 |
Why?
| | Melanoma | 4 | 2021 | 756 | 0.420 |
Why?
| | Contracture | 1 | 2013 | 21 | 0.420 |
Why?
| | Myotonic Dystrophy | 1 | 2013 | 10 | 0.420 |
Why?
| | Spinal Diseases | 1 | 2013 | 51 | 0.410 |
Why?
| | Quality Indicators, Health Care | 3 | 2010 | 307 | 0.400 |
Why?
| | Benchmarking | 2 | 2011 | 187 | 0.400 |
Why?
| | Surveys and Questionnaires | 12 | 2022 | 5803 | 0.390 |
Why?
| | Algorithms | 5 | 2025 | 1740 | 0.390 |
Why?
| | Peer Review, Research | 3 | 2007 | 42 | 0.380 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 282 | 0.380 |
Why?
| | Databases, Factual | 6 | 2024 | 1415 | 0.380 |
Why?
| | Beauty Culture | 4 | 2005 | 11 | 0.370 |
Why?
| | Bone Diseases, Metabolic | 2 | 2022 | 64 | 0.360 |
Why?
| | United States | 27 | 2024 | 14938 | 0.350 |
Why?
| | Total Quality Management | 1 | 2010 | 61 | 0.330 |
Why?
| | Internal Medicine | 5 | 2006 | 271 | 0.330 |
Why?
| | Databases, Bibliographic | 3 | 2004 | 32 | 0.330 |
Why?
| | Information Management | 2 | 2012 | 17 | 0.320 |
Why?
| | Transgender Persons | 2 | 2023 | 187 | 0.310 |
Why?
| | Fractures, Bone | 1 | 2013 | 397 | 0.290 |
Why?
| | Information Dissemination | 1 | 2010 | 221 | 0.280 |
Why?
| | Models, Statistical | 1 | 2012 | 663 | 0.280 |
Why?
| | Tretinoin | 1 | 2009 | 122 | 0.280 |
Why?
| | Internship and Residency | 4 | 2006 | 1187 | 0.260 |
Why?
| | Middle Aged | 24 | 2025 | 33604 | 0.250 |
Why?
| | Cause of Death | 1 | 2009 | 433 | 0.250 |
Why?
| | Anticholesteremic Agents | 2 | 2005 | 151 | 0.250 |
Why?
| | Female | 33 | 2025 | 73763 | 0.250 |
Why?
| | Adult | 21 | 2024 | 38201 | 0.250 |
Why?
| | Access to Information | 1 | 2006 | 49 | 0.250 |
Why?
| | Aged | 20 | 2025 | 24024 | 0.250 |
Why?
| | Disclosure | 1 | 2007 | 112 | 0.240 |
Why?
| | Clofibric Acid | 1 | 2005 | 1 | 0.240 |
Why?
| | Physician-Patient Relations | 5 | 2002 | 581 | 0.240 |
Why?
| | Adolescent | 20 | 2024 | 21564 | 0.240 |
Why?
| | Office Visits | 2 | 2002 | 95 | 0.230 |
Why?
| | Libraries, Digital | 1 | 2004 | 5 | 0.230 |
Why?
| | Archives | 1 | 2004 | 5 | 0.230 |
Why?
| | Remote Consultation | 1 | 2025 | 58 | 0.220 |
Why?
| | Biological Products | 2 | 2024 | 231 | 0.220 |
Why?
| | Health Information Interoperability | 1 | 2024 | 3 | 0.220 |
Why?
| | Observational Studies as Topic | 1 | 2025 | 121 | 0.220 |
Why?
| | Spain | 5 | 2021 | 45 | 0.220 |
Why?
| | Gemfibrozil | 2 | 2006 | 11 | 0.220 |
Why?
| | Comorbidity | 7 | 2022 | 1656 | 0.220 |
Why?
| | Lovastatin | 2 | 2006 | 38 | 0.220 |
Why?
| | Platelet Transfusion | 1 | 2024 | 72 | 0.210 |
Why?
| | Male | 33 | 2025 | 68260 | 0.210 |
Why?
| | Legislation as Topic | 1 | 2003 | 5 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2025 | 505 | 0.200 |
Why?
| | Pharmacists | 1 | 2025 | 260 | 0.200 |
Why?
| | Osteoporotic Fractures | 1 | 2023 | 61 | 0.190 |
Why?
| | Hospitalization | 6 | 2022 | 2235 | 0.190 |
Why?
| | Meningocele | 1 | 2022 | 2 | 0.190 |
Why?
| | Anticarcinogenic Agents | 1 | 2003 | 75 | 0.190 |
Why?
| | Programming Languages | 2 | 2021 | 25 | 0.190 |
Why?
| | Young Adult | 10 | 2023 | 13305 | 0.190 |
Why?
| | Cohort Studies | 9 | 2025 | 5697 | 0.190 |
Why?
| | Osteochondroma | 1 | 2022 | 9 | 0.190 |
Why?
| | Erythrocyte Transfusion | 1 | 2024 | 199 | 0.180 |
Why?
| | Blood-Retinal Barrier | 1 | 2021 | 14 | 0.180 |
Why?
| | Computer Communication Networks | 1 | 2021 | 33 | 0.180 |
Why?
| | Patient Acceptance of Health Care | 3 | 2023 | 858 | 0.180 |
Why?
| | Pregnancy Outcome | 1 | 2024 | 426 | 0.180 |
Why?
| | Depressive Disorder, Major | 1 | 2025 | 374 | 0.170 |
Why?
| | Drug Repositioning | 1 | 2021 | 36 | 0.170 |
Why?
| | Confidentiality | 1 | 2021 | 73 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 310 | 0.170 |
Why?
| | Perception | 1 | 2023 | 369 | 0.170 |
Why?
| | Osteoporosis | 1 | 2023 | 242 | 0.170 |
Why?
| | Quality of Health Care | 3 | 2024 | 654 | 0.170 |
Why?
| | Influenza, Human | 3 | 2021 | 614 | 0.160 |
Why?
| | Microvessels | 1 | 2021 | 86 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2023 | 7677 | 0.160 |
Why?
| | Natural Language Processing | 1 | 2021 | 95 | 0.160 |
Why?
| | Blood-Brain Barrier | 1 | 2021 | 141 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 375 | 0.160 |
Why?
| | Faculty, Medical | 1 | 2003 | 290 | 0.160 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2152 | 0.160 |
Why?
| | Computational Biology | 1 | 2004 | 649 | 0.160 |
Why?
| | Database Management Systems | 2 | 2012 | 51 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2025 | 564 | 0.150 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 229 | 0.150 |
Why?
| | Pandemics | 4 | 2021 | 1641 | 0.150 |
Why?
| | Pregnancy Complications | 1 | 2024 | 535 | 0.150 |
Why?
| | Blood Pressure | 1 | 2025 | 1739 | 0.150 |
Why?
| | Retina | 1 | 2021 | 305 | 0.150 |
Why?
| | Patient Care Team | 1 | 2024 | 647 | 0.150 |
Why?
| | Student Health Services | 1 | 2018 | 16 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 254 | 0.140 |
Why?
| | Language | 1 | 2021 | 305 | 0.140 |
Why?
| | Occupational Health | 1 | 2021 | 206 | 0.140 |
Why?
| | Patient Portals | 1 | 2018 | 45 | 0.140 |
Why?
| | Asthma | 2 | 2022 | 1888 | 0.140 |
Why?
| | Qualitative Research | 1 | 2025 | 1455 | 0.140 |
Why?
| | Health Plan Implementation | 1 | 2019 | 145 | 0.140 |
Why?
| | Artificial Intelligence | 1 | 2021 | 295 | 0.130 |
Why?
| | Communication | 2 | 2020 | 932 | 0.130 |
Why?
| | Republic of Korea | 3 | 2021 | 41 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1518 | 0.130 |
Why?
| | Phenotype | 1 | 2025 | 3139 | 0.130 |
Why?
| | Authorship | 2 | 2007 | 53 | 0.130 |
Why?
| | Health Care Surveys | 3 | 2016 | 565 | 0.120 |
Why?
| | Curriculum | 3 | 2024 | 1009 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 370 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 367 | 0.120 |
Why?
| | Education, Medical | 2 | 2011 | 268 | 0.120 |
Why?
| | Academic Medical Centers | 4 | 2023 | 514 | 0.110 |
Why?
| | Advance Care Planning | 1 | 2018 | 222 | 0.110 |
Why?
| | Review Literature as Topic | 2 | 2006 | 72 | 0.110 |
Why?
| | Hyperlipidemias | 1 | 2016 | 124 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 15909 | 0.110 |
Why?
| | Longevity | 1 | 2016 | 174 | 0.110 |
Why?
| | Transcriptome | 1 | 2021 | 967 | 0.110 |
Why?
| | Palliative Care | 1 | 2022 | 815 | 0.110 |
Why?
| | Health Education | 1 | 2018 | 357 | 0.110 |
Why?
| | Drosophila melanogaster | 1 | 2016 | 232 | 0.110 |
Why?
| | Trichotillomania | 1 | 2014 | 5 | 0.110 |
Why?
| | Health Personnel | 1 | 2021 | 732 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2016 | 1323 | 0.110 |
Why?
| | Prevalence | 4 | 2021 | 2727 | 0.110 |
Why?
| | Patient Satisfaction | 4 | 2002 | 688 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 578 | 0.100 |
Why?
| | Affective Symptoms | 1 | 2014 | 54 | 0.100 |
Why?
| | Hypertension, Pulmonary | 1 | 2025 | 1924 | 0.100 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 426 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1818 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1068 | 0.100 |
Why?
| | France | 2 | 2021 | 37 | 0.090 |
Why?
| | Referral and Consultation | 3 | 2023 | 793 | 0.090 |
Why?
| | Emergency Service, Hospital | 1 | 2023 | 2116 | 0.090 |
Why?
| | Medication Adherence | 1 | 2016 | 504 | 0.090 |
Why?
| | Obesity | 2 | 2022 | 2962 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1488 | 0.090 |
Why?
| | Ambulatory Care | 3 | 2006 | 575 | 0.090 |
Why?
| | Medical Records Systems, Computerized | 1 | 2012 | 95 | 0.090 |
Why?
| | Pregnancy | 1 | 2024 | 6829 | 0.090 |
Why?
| | Thalassemia | 1 | 2011 | 7 | 0.090 |
Why?
| | Planning Techniques | 1 | 2010 | 17 | 0.090 |
Why?
| | Quality Assurance, Health Care | 2 | 2010 | 331 | 0.090 |
Why?
| | Health Services Research | 2 | 2012 | 406 | 0.080 |
Why?
| | Organizational Objectives | 1 | 2010 | 66 | 0.080 |
Why?
| | Cost Savings | 1 | 2010 | 84 | 0.080 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 777 | 0.080 |
Why?
| | Disaster Planning | 1 | 2011 | 97 | 0.080 |
Why?
| | Heart Diseases | 1 | 2013 | 335 | 0.080 |
Why?
| | Child, Preschool | 4 | 2021 | 11158 | 0.080 |
Why?
| | Child | 7 | 2021 | 21921 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 28 | 0.080 |
Why?
| | Organizational Innovation | 1 | 2010 | 138 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 138 | 0.080 |
Why?
| | Safety Management | 1 | 2010 | 126 | 0.080 |
Why?
| | Organizational Culture | 1 | 2010 | 159 | 0.080 |
Why?
| | Brain | 1 | 2021 | 2792 | 0.070 |
Why?
| | Emotions | 1 | 2014 | 568 | 0.070 |
Why?
| | Administration, Topical | 1 | 2009 | 150 | 0.070 |
Why?
| | Infant | 3 | 2021 | 9574 | 0.070 |
Why?
| | Codes of Ethics | 1 | 2008 | 18 | 0.070 |
Why?
| | Human Experimentation | 1 | 2008 | 14 | 0.070 |
Why?
| | Colorado | 6 | 2024 | 4555 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2010 | 281 | 0.070 |
Why?
| | Age Factors | 3 | 2020 | 3256 | 0.070 |
Why?
| | Self-Evaluation Programs | 1 | 2007 | 6 | 0.070 |
Why?
| | Lung Diseases | 1 | 2013 | 785 | 0.060 |
Why?
| | Scientific Misconduct | 1 | 2007 | 12 | 0.060 |
Why?
| | Ethics, Research | 1 | 2007 | 34 | 0.060 |
Why?
| | Bibliometrics | 1 | 2007 | 65 | 0.060 |
Why?
| | Public Health | 1 | 2011 | 580 | 0.060 |
Why?
| | Students, Medical | 2 | 2011 | 355 | 0.060 |
Why?
| | Smallpox Vaccine | 1 | 2006 | 24 | 0.060 |
Why?
| | Neoplasms | 1 | 2021 | 2681 | 0.060 |
Why?
| | Hypolipidemic Agents | 1 | 2006 | 91 | 0.060 |
Why?
| | Knowledge | 1 | 2006 | 57 | 0.060 |
Why?
| | Medical Staff, Hospital | 1 | 2006 | 82 | 0.060 |
Why?
| | Family Practice | 1 | 2010 | 463 | 0.060 |
Why?
| | Clinical Clerkship | 1 | 2007 | 104 | 0.060 |
Why?
| | Research Design | 2 | 2014 | 1118 | 0.060 |
Why?
| | Vaccination | 2 | 2021 | 1437 | 0.060 |
Why?
| | Indiana | 1 | 2024 | 33 | 0.060 |
Why?
| | Health Level Seven | 1 | 2024 | 2 | 0.060 |
Why?
| | Vocabulary, Controlled | 1 | 2024 | 47 | 0.050 |
Why?
| | Data Accuracy | 1 | 2024 | 65 | 0.050 |
Why?
| | Editorial Policies | 1 | 2004 | 51 | 0.050 |
Why?
| | Blood Banks | 1 | 2024 | 47 | 0.050 |
Why?
| | Taxes | 1 | 2003 | 14 | 0.050 |
Why?
| | Teaching | 1 | 2006 | 233 | 0.050 |
Why?
| | Animals | 5 | 2022 | 37217 | 0.050 |
Why?
| | Risk Factors | 3 | 2021 | 10252 | 0.050 |
Why?
| | Medical Staff | 1 | 2002 | 17 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1374 | 0.050 |
Why?
| | Managed Care Programs | 2 | 2002 | 140 | 0.050 |
Why?
| | Testosterone Congeners | 1 | 2022 | 8 | 0.050 |
Why?
| | Chemoprevention | 1 | 2003 | 93 | 0.050 |
Why?
| | Absorptiometry, Photon | 1 | 2023 | 264 | 0.050 |
Why?
| | Documentation | 1 | 2004 | 198 | 0.050 |
Why?
| | Osteocytes | 1 | 2022 | 30 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5520 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2003 | 184 | 0.050 |
Why?
| | Gender Identity | 1 | 2023 | 126 | 0.050 |
Why?
| | Fibric Acids | 1 | 2021 | 3 | 0.050 |
Why?
| | Smoking Prevention | 1 | 2003 | 183 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 99 | 0.050 |
Why?
| | Canada | 1 | 2003 | 407 | 0.050 |
Why?
| | NFATC Transcription Factors | 1 | 2022 | 93 | 0.050 |
Why?
| | Receptors, Notch | 1 | 2022 | 87 | 0.040 |
Why?
| | Medical Oncology | 1 | 2004 | 304 | 0.040 |
Why?
| | Common Data Elements | 1 | 2021 | 14 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2007 | 853 | 0.040 |
Why?
| | Chondrogenesis | 1 | 2022 | 87 | 0.040 |
Why?
| | Ceftriaxone | 1 | 2021 | 20 | 0.040 |
Why?
| | Osteoblasts | 1 | 2022 | 131 | 0.040 |
Why?
| | Administrative Claims, Healthcare | 1 | 2021 | 26 | 0.040 |
Why?
| | Lopinavir | 1 | 2021 | 31 | 0.040 |
Why?
| | Fluoroquinolones | 1 | 2021 | 42 | 0.040 |
Why?
| | Sepsis | 1 | 2007 | 610 | 0.040 |
Why?
| | Blood Platelets | 1 | 2024 | 427 | 0.040 |
Why?
| | Germany | 1 | 2021 | 128 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 56 | 0.040 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2022 | 212 | 0.040 |
Why?
| | Ritonavir | 1 | 2021 | 75 | 0.040 |
Why?
| | Enoxaparin | 1 | 2021 | 64 | 0.040 |
Why?
| | China | 1 | 2021 | 214 | 0.040 |
Why?
| | Ambulatory Care Facilities | 1 | 2002 | 245 | 0.040 |
Why?
| | Abnormalities, Multiple | 1 | 2022 | 196 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2021 | 205 | 0.040 |
Why?
| | Azithromycin | 1 | 2021 | 97 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 319 | 0.040 |
Why?
| | Age Distribution | 1 | 2021 | 393 | 0.040 |
Why?
| | Osteogenesis | 1 | 2022 | 197 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2021 | 129 | 0.040 |
Why?
| | Biological Transport | 1 | 2021 | 403 | 0.040 |
Why?
| | Drug Combinations | 1 | 2021 | 346 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2021 | 453 | 0.040 |
Why?
| | Medically Underserved Area | 1 | 2000 | 90 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2021 | 6144 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2000 | 89 | 0.040 |
Why?
| | Patient Participation | 1 | 2023 | 428 | 0.040 |
Why?
| | Safety | 1 | 2021 | 347 | 0.040 |
Why?
| | Narration | 1 | 2020 | 64 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 253 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 984 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10923 | 0.040 |
Why?
| | Estradiol | 1 | 2022 | 525 | 0.040 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.040 |
Why?
| | Sexual Behavior | 1 | 2023 | 488 | 0.040 |
Why?
| | Testosterone | 1 | 2022 | 402 | 0.040 |
Why?
| | Skin | 1 | 2003 | 754 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2851 | 0.040 |
Why?
| | Erythrocytes | 1 | 2024 | 701 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2019 | 125 | 0.040 |
Why?
| | Occult Blood | 1 | 2018 | 34 | 0.040 |
Why?
| | Family | 1 | 2002 | 677 | 0.030 |
Why?
| | Overweight | 1 | 2022 | 571 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 496 | 0.030 |
Why?
| | Vitamin D | 1 | 2021 | 393 | 0.030 |
Why?
| | Physicians | 1 | 2006 | 932 | 0.030 |
Why?
| | Fiber Optic Technology | 1 | 1997 | 23 | 0.030 |
Why?
| | Spiro Compounds | 1 | 1996 | 14 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1482 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2022 | 791 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 502 | 0.030 |
Why?
| | Growth Hormone | 1 | 1996 | 102 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 1997 | 60 | 0.030 |
Why?
| | Sexual Behavior, Animal | 1 | 2016 | 58 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 2065 | 0.030 |
Why?
| | Testis | 1 | 2016 | 157 | 0.030 |
Why?
| | Cooperative Behavior | 2 | 2011 | 457 | 0.030 |
Why?
| | Colonoscopy | 1 | 2018 | 243 | 0.030 |
Why?
| | Prospective Studies | 3 | 2003 | 7554 | 0.030 |
Why?
| | Internationality | 1 | 2016 | 158 | 0.030 |
Why?
| | United States Public Health Service | 1 | 2015 | 10 | 0.030 |
Why?
| | Smoking | 1 | 2003 | 1591 | 0.030 |
Why?
| | Reproduction | 1 | 2016 | 202 | 0.030 |
Why?
| | Mice | 2 | 2022 | 17814 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 279 | 0.030 |
Why?
| | Sex Factors | 1 | 2020 | 2044 | 0.030 |
Why?
| | Neoplasms, Radiation-Induced | 2 | 2005 | 91 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 916 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1996 | 325 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1992 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2016 | 243 | 0.030 |
Why?
| | Down-Regulation | 1 | 2016 | 635 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1746 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 958 | 0.030 |
Why?
| | Patient Education as Topic | 1 | 2018 | 766 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6851 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1986 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 851 | 0.030 |
Why?
| | Indoles | 1 | 1996 | 414 | 0.030 |
Why?
| | Clinical Competence | 3 | 2007 | 1149 | 0.030 |
Why?
| | Quality of Life | 2 | 2019 | 2954 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2073 | 0.020 |
Why?
| | Data Collection | 2 | 2006 | 657 | 0.020 |
Why?
| | Rats | 1 | 2021 | 5594 | 0.020 |
Why?
| | Genotype | 1 | 2016 | 1842 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2022 | 5798 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2749 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 3987 | 0.020 |
Why?
| | Problem-Based Learning | 1 | 2011 | 98 | 0.020 |
Why?
| | Schools, Medical | 1 | 2011 | 151 | 0.020 |
Why?
| | Health Surveys | 1 | 2011 | 504 | 0.020 |
Why?
| | MEDLINE | 1 | 2007 | 22 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5086 | 0.020 |
Why?
| | Clofibrate | 1 | 2006 | 3 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1341 | 0.020 |
Why?
| | Bezafibrate | 1 | 2006 | 10 | 0.020 |
Why?
| | Pravastatin | 1 | 2006 | 41 | 0.020 |
Why?
| | Depression | 1 | 2016 | 1466 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2006 | 66 | 0.020 |
Why?
| | Simvastatin | 1 | 2006 | 63 | 0.020 |
Why?
| | Bioterrorism | 1 | 2006 | 30 | 0.020 |
Why?
| | Quality Control | 1 | 2006 | 171 | 0.020 |
Why?
| | Electronic Mail | 1 | 2006 | 61 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2008 | 272 | 0.010 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2006 | 82 | 0.010 |
Why?
| | Research Personnel | 1 | 2007 | 182 | 0.010 |
Why?
| | Pyrroles | 1 | 2006 | 209 | 0.010 |
Why?
| | Reproducibility of Results | 2 | 2006 | 3307 | 0.010 |
Why?
| | Hypermedia | 1 | 2004 | 1 | 0.010 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 190 | 0.010 |
Why?
| | Computers | 1 | 2004 | 69 | 0.010 |
Why?
| | Educational Measurement | 1 | 2007 | 299 | 0.010 |
Why?
| | Odds Ratio | 1 | 2006 | 1044 | 0.010 |
Why?
| | Beds | 1 | 2003 | 11 | 0.010 |
Why?
| | Interprofessional Relations | 1 | 2006 | 290 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2844 | 0.010 |
Why?
| | Professional Autonomy | 1 | 2002 | 30 | 0.010 |
Why?
| | Gatekeeping | 1 | 2002 | 3 | 0.010 |
Why?
| | Probability | 1 | 2002 | 308 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2490 | 0.010 |
Why?
| | Pilot Projects | 1 | 2007 | 1765 | 0.010 |
Why?
| | Research | 1 | 2004 | 451 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 363 | 0.010 |
Why?
| | Incidence | 1 | 2006 | 2747 | 0.010 |
Why?
| | Outpatients | 1 | 2002 | 419 | 0.010 |
Why?
| | Software | 1 | 2004 | 668 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 175 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1296 | 0.010 |
Why?
| | Administration, Oral | 1 | 1996 | 788 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2049 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1996 | 1949 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1997 | 3523 | 0.000 |
Why?
| | Blood Glucose | 1 | 1996 | 2239 | 0.000 |
Why?
|
|
Schilling's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|